Spores of Bacillus subtilis are encased in a protein coat composed of ∼80 different proteins. Recently, we reconstituted the basement layer of the coat, composed of two structural proteins (SpoVM and SpoIVA) around spore-sized silica beads encased in a lipid bilayer, to create synthetic spore-like particles termed 'SSHELs'. We demonstrated that SSHELs could display thousands of copies of proteins and small molecules of interest covalently linked to SpoIVA. In this study, we investigated the efficacy of SSHELs in delivering vaccines. We show that intramuscular vaccination of mice with undecorated one micron-diameter SSHELs elicited an antibody response against SpoIVA. We further demonstrate that SSHELs covalently modified with a catalytically inactivated staphylococcal alpha toxin variant (Hla H35L ), without an adjuvant, resulted in improved protection against Staphylococcus aureus infection in a bacteremia model as compared to vaccination with the antigen alone. Although vaccination with either Hla H35L or Hla H35L conjugated to SSHELs similarly elicited the production of neutralizing antibodies to Hla, we found that a subset of memory T cells was differentially activated when the antigen was delivered on SSHELs. We propose that the particulate nature of SSHELs elicits a more robust immune response to the vaccine that results in superior protection against subsequent S. aureus infection.
INTRODUCTION
Bacillus subtilis is a common Gram-positive, rod-shaped soil bacterium often used in microbiology as a model organism for the study of cellular differentiation and morphogenesis (Higgins and Dworkin 2012; Tan and Ramamurthi 2014) . Under nutrient deprivation, B. subtilis divides asymmetrically producing genetically identical yet morphologically distinct daughter cells, consisting of a rod-shaped mother cell harboring an intracellular, roughly spherical, forespore, that undergo different cellular fates in a process called sporulation. A hallmark of sporulation is the deposition of ∼80 spore coat proteins, produced in the mother cell, onto the outer surface of the forespore, creating a thick proteinaceous shell that protects the mature spore from chemical and enzymatic perturbations (Henriques and Moran 2007; McKenney, Driks and Eichenberger 2013) . The robust nature of the spore combined with the genetically tractable system in B. subtilis has spurred numerous investigations into applications wherein recombinant proteins are displayed on the surface of the spore via gene fusions to outer spore coat proteins. Such platforms have been useful in displaying enzymes for bioremediation (Wu, Mulchandani and Chen 2008; Hinc et al. 2010) and industrial production (Florin et al. 1991; Chen et al. 2015a,b) , small molecules and dyes for whole-cell bio sensing systems (Date, Pasini and Daunert 2010) , and antigens for vaccines (Mauriello et al. 2004; Duc le et al. 2007; Isticato and Ricca 2014; Potocki et al. 2017; Dai et al. 2018) .
Coat morphogenesis in B. subtilis initiates with the assembly of a basement layer around the forespore. The structural component of the basement layer is a protein termed SpoIVA (Roels, Driks and Losick 1992; Price and Losick 1999) that displays a multi-domain architecture (Castaing et al. 2014) . SpoIVA binds and hydrolyzes ATP to irreversibly polymerize around the forespore to form a stable platform for the proper assembly of the coat (Ramamurthi and Losick 2008; Castaing et al. 2013) . SpoIVA is tethered to the surface of the forespore via a small 26-aa protein, SpoVM (Levin et al. 1993; Ramamurthi, Clapham and Losick 2006) , that preferentially localizes to the forespore surface by recognizing its convex shape (Ramamurthi et al. 2009; Gill et al. 2015; Kim et al. 2017) . Recently, we reconstituted the basement layer of the coat around spherical supported lipid bilayers (SSLBs; (Bayerl and Bloom 1990; Gopalakrishnan et al. 2009 )) using purified SpoIVA and synthesized SpoVM peptide in the presence of ATP to create artificial spore-like particles termed synthetic spore husk-encased lipid bilayers (SSHELs; (Wu et al. 2015) ). By modifying SpoIVA on specific residues with so-called 'click-chemistry' reagents, we demonstrated that SSHELs could covalently display thousands of copies of small molecules and proteins of interest and proposed that these particles could be used as a versatile vaccine display platform, since they provided several potential benefits. Principally, SSHELs are composed entirely of defined materials, which eschew the use of a living organism, and can avoid complications arising from horizontal gene transfer or the use of extraneous components that may interfere with the function of a displayed entity.
Here we tested the ability of SSHELs to deliver a candidate vaccine against Staphylococcus aureus infection. Staphylococcus aureus is a leading bacterial pathogen in adult and pediatric populations, and its myriad clinical manifestations include soft-tissue infection, bloodstream infection and life-threatening pneumonia (Sheagren 1984a,b; Lowy 1998) . The growing presence of antibiotic resistant strains combined with high morbidity and mortality have warranted novel approaches to combat this community-acquired and nosocomial pathogen (Dufour et al. 2002; Gillet et al. 2002; Kollef et al. 2006) . It has been shown that vaccination of mice with an inactive variant of the β-barrel, pore-forming alpha toxin protein (Hla H35L ), a key virulence factor in S. aureus pathogenicity (O'Reilly et al. 1986; Patel et al. 1987) , provides protection against S. aureus infection of the lung and skin (Menzies and Kernodle 1994; Bubeck Wardenburg and Schneewind 2008; Ragle and Bubeck Wardenburg 2009; Kennedy et al. 2010) . To assess the potential for SSHELs to serve as an antigen delivery platform, we created SSHEL::Hla H35L conjugates. We found that vaccination with SSHEL::Hla H35L induced Hla H35L -specific antibody and T cell responses in mice, and provided enhanced protection from S. aureus infection in a murine bacteremia model.
RESULTS

Assembly of SSHEL particles that covalently display a model vaccine
We recently described the in vitro reconstitution of the B. subtilis spore coat atop silica beads to construct synthetic spore-like particles that we termed 'SSHELs' (Wu et al. 2015) . To achieve this, we first applied a single phospholipid bilayer, composed of a mix of synthetic lipids that mimicked the composition of the E. coli plasma membrane, around 1 μm-diameter silica beads to build spherical supported lipid bilayers (SSLBs; Fig. 1A ). Next, we added synthesized SpoVM peptide, and incubated the resulting SpoVM-coated SSLBs with purified SpoIVA protein in buffer containing ATP to drive polymerization of SpoIVA around the particles, to create SSHELs. The SpoIVA we employed was a fully functional cysteine-less variant into which we engineered a single N-terminal Cys residue, which we then modified with trans-cyclooctene (TCO) that undergoes a copper-free Diels-Alder 'click chemistry' reaction with tetrazine (Liang et al. 2012 ) that allows for the covalent display of proteins on the surface of the SSHELs (Fig. 1A) . To evaluate the utility of SSHELs as a vaccine display platform, we chose an inactive variant of S. aureus alpha-hemolysin protein (Hla) in which His35 was substituted with Lys, as a model antigen (Menzies and Kernodle 1994; Bubeck Wardenburg and Schneewind 2008; Kennedy et al. 2010) . Purified Hla H35L molecules, labeled with the fluorescent dye AlexaFluor488, were modified on free amines with tetrazine and conjugated onto SSHELs via the TCO modification on SpoIVA molecules (Fig. 1A) . Epifluorescence microscopy of SSHELs conjugated with fluorescently labeled Hla H35L revealed that tetrazine-modified Hla H35L -AF488, but not Hla H35L -AF488 that was unmodified, coated the particles in a largely uniform pattern (Fig. 1B) . Quantification of the fluorescence by flow cytometry and comparison to a known set of standards revealed that each SSHEL displayed a mean of approximately 12 000 molecules of equivalent soluble fluorescence (Fig. 1C) . By considering the degree of labeling (see Material and Methods), we calculated that each SSHEL displays a mean of approximately 16 000 Hla H35L molecules (Fig. 1C) .
SSHEL-based vaccination elicits protective immunity against S. aureus infection
Bacterial cells, including spores, that display vaccine antigens of interest have been shown to display an immune-stimulatory effect. This is presumably due to certain molecules harbored by the bacterium, termed 'microbe-associated molecular patterns' (Barnes et al. 2007; Pan, Kim and Yun 2012) . Furthermore, the particulate nature of the cells has been proposed to additionally contribute to this effect (Lebre et al. 2017 samples collected 2 weeks after each immunization were tested for SpoIVA-specific IgG content by ELISA. In mice vaccinated intranasally, three vaccinations were required to elicit a robust antibody response towards SpoIVA and the inclusion of adjuvant did not significantly alter the amount of anti-SpoIVA IgG detected ( Fig. 2A) . In contrast, a single vaccination via the IM route induced a strong SpoIVA-specific IgG response that was enhanced with each additional vaccination but not additionally enhanced by adjuvants (Fig. 2B ). This suggested intrinsic immune stimulatory properties that we hypothesized could be harnessed to create an adjuvant-free vaccine platform that would elicit specific antibody responses against antigens displayed on its surface.
To test the ability of vaccine antigens displayed on SSHELs to protect against subsequent S. aureus infection, we first determined the optimal infection dose of S. aureus via the intravenous route. Infection of mice with 8 × 10 7 or 4 × 10 7 colony forming units (CFU) of S. aureus resulted in rapid killing of 100% of the mice in 4 days or less, but reducing the infection dosage to just 2 × 10 7 or 8 × 10 6 resulted in killing 33%-66% of mice, respectively ( Fig. 3A) . Given the relatively narrow infection dosage window that was optimal for delayed killing, we decided to perform challenge experiments after immunization with 3 × 10 7 CFU of as well as vaccination with purified Hla H35L protein. Thus, the production of neutralizing antibodies alone was insufficient to explain the enhanced protection conferred by delivery of Hla H35L via SSHELs.
Vaccine delivery via SSHELs induced an antigen-specific T cell response
Since serum IgG levels and Hla neutralization were similar regardless of whether we immunized with SSHEL::Hla H35L or Hla H35L ( Fig. 4A and B 
DISCUSSION
The use of bacteria, and especially bacterial spores, as a display platform and delivery vehicle for vaccines has been previously proposed and studied quite extensively (Ning et al. 2011; Wang, Wang and Yang 2017; Bartels et al. 2018) . We suggest that the strategy presented in this report, using synthetic spores termed 'SSHELs' that were covalently decorated with vaccine antigens, may be used as an additional strategy in ongoing efforts to deliver vaccines on particles. SSHELs offer several advantages. Primarily, SSHELs are constructed entirely from defined components (silica, phospholipids and two proteins) and do not harbor any genetic material. Thus, concerns about horizontal gene transfer, release of genetically modified organisms into the environment, and the use of extraneous factors contained in a cell that may not be directly required for vaccine delivery are obviated. Second, although we herein reported the delivery of a single antigen, we envision that we could easily adapt the protocol to accommodate the covalent attachment of multiple antigens, in defined ratios, to permit the delivery of several vaccines at once. Finally, as reported previously for sporedisplayed vaccines (Huang et al. 2008) , SSHEL-displayed vaccines can apparently elicit immune responses without the addition of adjuvants to stimulate the immune system. Given the relatively few components used to construct SSHELs, we propose that this feature is due to the particulate, roughly bacterialsized, nature of the vehicle, which allows for interactions with professional antigen presenting cells that promote appropriate presentation of the vaccine epitopes. Indeed, in our studies, delivery of far fewer vaccine molecules per mouse resulted in the generation of similar levels of antibodies compared to delivery of the antigen alone, suggesting that display of vaccines on SSHELs may result in an intrinsic stimulation of the immune system. A surprising result of our studies was the observation that, although vaccination of mice with SSHELs displaying Hla H35L produced a similar titer of neutralizing antibodies as vaccination with the antigen alone, vaccination with SSHEL-anchored Hla H35L resulted in a higher protective efficacy of the vaccine to subsequent infection with S. aureus in a bacteremia model. This suggested that an additional component of the immune system, beyond just antibody production, may contribute to this protection. Indeed, we observed that vaccination with SSHEL::Hla H35L resulted in increased activation of effector T cells that were IFNγ + and TNFα + .
Further work will be needed to establish the relative contribution of antibody-and T cell-mediated immunity to the observed protection, but our results are consistent with the increasing appreciation that protective immunity against S. aureus involves both humoral and cellular responses and critically depends on the balance between IFNγ (Th1)-and IL-17 (Th17)-secreting T cells (Gaidamakova et al. 2012; Karauzum et al. 2017) . Similarly, it was shown previously in a mouse pneumonia infection model that S. aureus induces T cells positive for IFNγ and IL-1β (Bubeck Wardenburg and Schneewind 2008) , and that TNFα and IL-6 were induced in humans with culture-verified S. aureus septicemia (Soderquist, Sundqvist and Vikerfors 1992; Soderquist et al. 1998) . TNFα was also shown to enhance neutrophil killing of opsonized S. aureus (Bates, Ferrante and Beard 1991) , possibly by the enhanced production of reactive oxygen species (Guerra et al. 2017) . Finally, the increase in IFNγ production we observed to correlate with the protective efficacy of SSHEL-delivered vaccine is consistent with the report that injection of purified recombinant IFNγ into mice 2 days prior or 3 days following inoculation with S. aureus significantly enhanced mouse survival, which was correlated to increased phagocytosis and bacterial clearance from liver and kidneys (Zhao, Nilsson and Tarkowski 1998) . Thus, the ability of SSHEL-based vaccination to induce both T cell and antibody responses against displayed antigens suggests that it may represent a valuable vaccination strategy for those infections that require protective immunity mediated by both humoral and cellular responses.
MATERIAL AND METHODS
Protein purification and labeling
His 6 -tagged SpoIVA single-cysteine variant was overproduced in E. coli BL21(DE3) and purified using Ni 2+ affinity chromatography (Qiagen), and subsequently by ion-exchange chromatography (MonoQ; Pharmacia) as described previously (Wu et al. 2015) . gated on CD44 + Foxp3 − CD4 T cells (n = 3-6 mice/group). Significant differences between groups were analyzed by Mann-Whitney test: * : P ≤ 0.04; * * : P ≤ 0.0098.
For purification of His 6 -tagged Hla H35L , hla was PCR-amplified from S. aureus chromosomal DNA and cloned into the pET28a vector (EMD Biosciences) using the 5 NcoI and 3 XhoI restriction sites. The H35L mutation was introduced into the hla gene using the Quikchange kit (Agilent). His 6 -Hla H35L was overproduced in exponentially growing E. coli BL21(DE3) in LB medium by addition of 1 mM IPTG for 4 h at 37
• C. Harvested cells were resuspended in Buffer A (50 mM Tris pH 7.5, 150 mM NaCl) and disrupted by French press at ca. 12 500 psi. Cell debris was removed by centrifugation at 30 000 × g and the clarified supernatant was loaded onto a Ni 2+ -NTA agarose affinity column equilibrated with Buffer A. The column was washed with 20 column volumes of Buffer A containing 20 mM imidazole, and finally eluted with Buffer A containing 250 mM imidazole. His 6 -Hla H35L was next purified by size exclusion chromatography (Sephadex; Pharmacia). For click chemistry conjugation, SpoIVA was labeled with trans-Cyclooctene-PEG3-Maleimide (TCO), and Hla H35L was labeled with Methyltetrazin-PEG3-NHS ester kit as described by the manufacturer (Click Chemistry Tools). In brief, 20-fold molar excess of maleimide or NHS ester reagent was added to the protein samples and incubated overnight at 4
• C, and the excess reagent was removed by Zeba Spin Desalting Column (Thermo Scientific). For labeling Hla H35L with AlexaFluor-488, Hla H35L was incubated with 3-fold molar excess of Alexa 488 Succinimidyl Ester (Life Technologies) for 1 h at room temperature and desalted with Zeba Spin Desalting Column prior to labeling with Methyltetrazine. Degree of labeling of AlexaFluor-488 to Hla H35A was estimated using absorbance measurements at A 280 and A 495 , and a correction factor of 0.11 for AlexaFluor-488 dye (Molecular probes). Degree of labeling was calculated to be ∼0.7 AlexaFluor-488 molecules per Hla H35A protein.
SSLB preparation
SSLBs were made largely as previously described (Bayerl and Bloom 1990; Gopalakrishnan et al. 2009 ). In brief, liposomes were produced by the liquid sonication method using 200 μl (10 mg/ml) of defined lipid components to mimic the composition of the E. coli plasma membrane: DOPE wt/wt 67%; DOPG wt/wt 23.2%; cardiolipin wt/wt 9.8% (Avanti), that were first evaporated under vacuum overnight at room temperature and hydrated in 1 ml ultrapure water. Resuspended lipids were subjected to five freeze-thaw cycles between ethanol-dry ice bath and 42
• C water bath, followed by sonication until the suspension became transparent. Debris was removed by centrifugation at 13 000 g for 10 min, and the supernatant containing small unilamellar vesicles was retained. Silica beads (1 μm, 10 mg/ml) (PolySciences) were prepared for coating by washing three times each in 1 ml ultrapure water, followed by methanol and 1M NaOH. The beads were rinsed and resuspended in 200 μl ul-trapure water. The SSLBs were constructed by mixing the silica beads with 400 μl prepared liposomes and 1 mM CaCl 2 , and incubated at 42
• C for 30 min. After vortexing, SSLBs were collected by centrifugation at 13 000 g for 2 min, washed three times with ultrapure water and resuspended in 1 ml Buffer B (50 mM Tris and 400 mM NaCl at pH7.5).
SSHEL particle construction
SSHELs were constructed largely as described previously (Wu et al. 2015) . Briefly, SpoVM was synthesized as a 26-amino-acid peptide (Biomatik Corp.) and incubated at 10 μM (final concentration) with 6 mg/ml 1 μm-diameter SSLBs in 200 μl Buffer B, overnight at 25
• C following a program of alternate shaking (750 rpm) and resting every 5 min. SpoVM coated SSLBs were collected by centrifugation at 13 000 × g for 1 min, and then incubated with ∼1.5 μM trans-cyclooctene labeled SpoIVA in a final volume of 400 μl Buffer B containing 10 mM MgC 2 and 4 mM ATP, overnight at room temperature with gentle inversion covered from light. SSHEL particles were collected by centrifugation and resuspended in 400 μl Buffer A (50 mM Tris and 150 mM NaCl at pH 7.5) containing ∼1.5 μM methyltetrazine-labeled Hla H35L , and incubated overnight at room temperature with gentle inversion covered from light. SSHEL particles from multiple 400 μl samples were then collected by centrifugation and pooled together and washed thrice with 1 ml Buffer B. SSHELs were visualized using epifluorescence microscopy as previously described (Tan et al. 2015) . Briefly, 5 μl SSHEL suspensions were placed on a poly-d-lysine Coated Glass Bottom Culture Dish (Mattek Corp.) and covered by 1% agarose pad made with distilled water. Images were viewed and captured with a Delta Vision Core microscope with a Photometrics Coolsnap HQ2 camera (Applied Precision). Median fluorescence intensities for an entire SSHEL particle on a single plane were quantified using SoftWorx software. To estimate the number of Hla copies displayed on each SSHEL, the median fluorescence intensity (MFI) of SSHEL particles containing AlexaFluor-488 labeled Hla H35L was measured using a BD FACSCanto II (BD Biosciences) flow cytometer and BD FACSDiva software. The median fluorescence intensities were converted to molecules of equivalent soluble fluorochrome (MESF) of the SSHELs via a standard curve relating the fluorescence peaks of commercial QuantumTM AlexaFluor-488 beads to their MESF values (Bangs Laboratories, Inc.); the estimated fluorophore to protein ratio (∼0.7) was used for calculating the Hla H35L copy number.
Preparation of inoculum for infection
For bacterial challenges, 20 ml of brain heart infusion broth (BHI, Difco Laboratories, Detroit, Mich.) were inoculated with a swab of CA-MRSA USA300 (Los Angeles County clone, LAC) from a freshly streaked blood agar plate and culture was grown for 18 h at 37
• C with shaking at 230 rpm. Cells were harvested by centrifugation at room temperature, the cell pellet was washed twice with phosphate buffered saline (PBS) and re-suspended in PBS. Aliquots were prepared and stored at −80 • C until further use. Aliquots were periodically thawed and plated to confirm CFU/ml after storage.
Animals
Female C57BL/6J mice were purchased from The Jackson Laboratory, Bar Harbor, ME. Starting age of mice in each experiment was 6 weeks for active vaccination studies. Mice were maintained under pathogen-free conditions and fed laboratory chow and water ad libitum. All animal experiments were conducted in compliance with guidelines approved by NIAID Institutional Animal Care and Use Committees (IACUC). Starting Block (Thermo Fisher) for 2 h at room temperature. Serum samples were prepared in semi-log dilutions in starting from 1:10 2 to 1:10 7 in a 96-well plate using Staring Block as diluent. Plates were washed three times and sample dilutions were applied in 100 μl volume/well. Plates were incubated for 1 h at room temperature and washed thrice before applying the conjugate, goat anti-mouse IgG (H&L)-HRP, (Horse Radish Peroxidase) in a 1:2000 dilution. Plates were incubated for 1 h at room temperature, washed as described above and incubated with TMB (3,3 ,5,5 -tetramethylbenzidine) to detect HRP for 15 min. Optical density at 450 nm was measured using a VersamaxTM plate reader (Molecular Devices CA). Data analysis for full dilution curves was performed using Graph Pad PRISM 7.
Vaccination and infection
Hla toxin neutralization assay
Hla neutralization assays were performed with rabbit red blood cells (RBCs) as previously described (Adhikari et al. 2012) . Briefly, a concentration of wildtype recombinant Hla that resulted in 100% lysis of RBCs was co-cultured with 2% rabbit RBCs in the presence or absence of serially diluted mouse sera. Cells were centrifuged and absorbance of supernatants was determined at 416 nm in a Beckman Coulter DTX 880 plate reader.
Cell isolation, in vitro stimulation and flow cytometry
Single-cell suspensions of spleens were prepared by mechanical disruption and dispersion through 40-μm pore-size cell strainers. Red blood cells were lysed with ACK lysis buffer (Lonza), washed and once more filtered through 40-μm pore-size cell strainers. For intracellular cytokine staining, cells were resuspended in Dulbecco's minimum essential medium (Life Technologies), at 2 × 10 6 cells per well in a 96-well plate and incubated in the presence or absence of anti-CDC3/CD28 or Hla H35L at 37
• C, 5% carbon dioxide for 4 h in the presence of brefeldin A. Cells were then surface stained and fixed/permeabilized overnight, and intracellular staining was performed the next day. Antibodies against mouse surface and intracellular antigens, and cytokines (eBioscience, Biolegend, and BD Biosciences) were used in 10-color flow cytometry, either biotinylated or directly conjugated. The antibodies used were directed against CD4 (clone RM4-5), CD8 (clone 52-6.7), CD44 (clone IM7), Foxp3 (clone FJK-16s), CD45 (clone 30-F11), TNF-α (clone MP6-XT22), IFN-γ (clone XMG1.2) and IL-17A (clone 17B7). Near-infrared fixable live-dead cell stain (Molecular Probes) was used according to the manufacturer's protocol. All data were acquired on a LSR Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star) version 10.1r5.
